Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'

Detalles Bibliográficos
Autores principales: Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396113/
https://www.ncbi.nlm.nih.gov/pubmed/28324884
http://dx.doi.org/10.1038/bjc.2017.58
_version_ 1783230006742220800
author Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
author_facet Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
author_sort Imafuku, Keisuke
collection PubMed
description
format Online
Article
Text
id pubmed-5396113
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53961132018-04-11 Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy' Imafuku, Keisuke Yoshino, Koji Yamaguchi, Kei Tsuboi, Satoshi Ohara, Kuniaki Hata, Hiroo Br J Cancer Letter to the Editor Nature Publishing Group 2017-04-11 2017-03-21 /pmc/articles/PMC5396113/ /pubmed/28324884 http://dx.doi.org/10.1038/bjc.2017.58 Text en Copyright © 2017 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Letter to the Editor
Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title_full Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title_fullStr Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title_full_unstemmed Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title_short Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
title_sort comment on ‘efficacy and toxicity of treatment with the anti-ctla-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-pd-1 therapy'
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396113/
https://www.ncbi.nlm.nih.gov/pubmed/28324884
http://dx.doi.org/10.1038/bjc.2017.58
work_keys_str_mv AT imafukukeisuke commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy
AT yoshinokoji commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy
AT yamaguchikei commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy
AT tsuboisatoshi commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy
AT oharakuniaki commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy
AT hatahiroo commentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy

Ejemplares similares